Across TCGA pan-cancer cohorts, CPSF4L Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CPSF4L data layer compared with 20 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher CPSF4L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CPSF4L expression acts as an unfavorable survival marker.

KIRC and ACC are the cancer types where CPSF4L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.152	0.874	<.001	12	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: CPSF4L tumor-vs-normal RNA expression · all CPSF4L data types